Sharon Katz
Psychiatric/Mental Health · Jenkintown, PANPI 1881756856
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,000 of the $50,544 with a category attached, or 83.1%. AbbVie accounts for 89.4% of it on its own, with 16 other manufacturers making up the rest. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 379 payments — averaging $133.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$45K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$651
- Axsome Therapeutics, Inc.$553
- E.r. Squibb & Sons, L.L.C.$530
- Neurocrine Biosciences, Inc.$498
- plus $2K from 11 others
What the payments were for
- Consulting fees$1150%
- Speaking & faculty fees$42,00083%
- Travel & lodging$1,0592%
- Food & beverage$7,24414%
- Education$1250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 203 | $45,167 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $1,235 |
| Otsuka America Pharmaceutical, Inc. | 19 | $651 |
| Axsome Therapeutics, Inc. | 10 | $553 |
| E.r. Squibb & Sons, L.L.C. | 13 | $530 |
| Neurocrine Biosciences, Inc. | 15 | $498 |
| Alkermes, Inc. | 10 | $377 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $353 |
| Johnson & Johnson | 7 | $346 |
| Teva Pharmaceuticals USA, Inc. | 4 | $172 |
| Corium, LLC | 3 | $168 |
| Janssen Scientific Affairs, LLC | 2 | $145 |
| Sunovion Pharmaceuticals Inc. | 14 | $136 |
| Bausch Health US, LLC | 5 | $83 |
| Tris Pharma Inc | 3 | $63 |
| Vanda Pharmaceuticals Inc. | 3 | $45 |
| UCB, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,544 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $195,872 |
| VraylarCariprazine Hcl | 64 | $104,691 |
| AuvelityDextromethorphan Hbr/Bupropion | 17 | $20,035 |
| RexultiBrexpiprazole | 12 | $17,452 |
| Duloxetine Hcl | 151 | $2,465 |
| Bupropion XlBupropion Hcl | 102 | $1,435 |
| Gabapentin | 109 | $1,277 |
| Clonazepam | 135 | $1,181 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 38 | $1,163 |
| Mirtazapine | 75 | $1,131 |
| Quetiapine Fumarate | 86 | $781 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 24 | $763 |
| Buspirone Hcl | 76 | $634 |
| Olanzapine | 51 | $580 |
| Lamotrigine | 66 | $527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $498 | $195,87224 claims |
| AbbVieVraylar | $45,167 | $104,69164 claims |
| Axsome Therapeutics, Inc.Auvelity | $553 | $20,03517 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $651 | $17,45212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Jenkintown
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Jennifer BowmanCanonsburg$48K
- Dylan KilmerGreenfield Township$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.